|
Thursday November 2, 2000 COMPANY PRESS RELEASE Transgenomic, Inc. Conference Call Archived On the Web and Via Telephone Archival of Conference Call Notification Release SAN JOSE, Calif. and OMAHA, Neb., Nov. 2, 2000-- In connection with Transgenomic, Inc.'s reporting of third quarter financial results, you are invited to listen to the archived conference call that is currently available as of today, Thursday, November 2, 2000. The call will be archived by way of telephone through next Thursday, November 9, 2000 and will remain archived on the Internet through Tuesday, January 30, 2001. The archived call can also be accessed via the Internet at www.transgenomic.com or by calling 800-753-8546 or 402-220-0685.
(Minimum requirements to listen to broadcast on the Internet: The RealPlayer software, downloadable free from www.real.com/products/player/index.html, and at least a 14.4Kbps connection to the Internet. If you experience problems listening to the broadcast, send an e-mail to webmaster@vdat.com.) About Transgenomic Transgenomic provides innovative research tools to the genomics segment of the life sciences industry. These tools enable researchers to discover and understand variation in the human genetic code, or genome, in order to accelerate and improve drug development and diagnostics. The company believes its WAVE® System will become a leading tool to analyze genetic mutations. The WAVE® System allows researchers to analyze both known and unknown genetic mutations faster, with more accuracy and at a lower cost than other commercially available techniques. As efforts to sequence the human genome near completion, understanding variations in the genetic sequence, or mutation analysis, is becoming the vital link to the development of new diagnostic and therapeutic products. By comparing genetic mutations in the genome to the occurrence of diseases or particular traits, correlation can be made between genes and specific diseases or traits. The WAVE® System, unlike tools employing more conventional technologies, can detect these genetic mutations without previous knowledge of their existence or position. As a result, the WAVE® System provides researchers a more accurate and efficient means of performing the experiments necessary to identify mutations and to correlate the relationships between mutations and diseases. Forward-Looking Statement This press release may contain forward-looking statements that reflect management's current views and estimates of future economic circumstances, industry conditions, company performance and financial results. Such statements are subject to certain factors, risks and uncertainties described from time to time in Transgenomic, Inc.'s reports to the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release. For more information, contact:
|